Overview

* Gossamer Bio ( GOSS ) Q3 revenue from collaborations rises to $13.3 mln, up from $9.5 mln in 2024

* Net loss for Q3 widens to $48.2 mln from $30.8 mln in 2024

Outlook

* Company expects topline results from PROSERA Phase 3 Study in February 2026

* First site activated for SERANATA Phase 3 Study in PH-ILD

* Company's cash reserves expected to fund operations into 2027

Result Drivers

* R&D EXPENSES - Increase in R&D expenses to $45.5 mln from $34.9 mln in 2024 due to ongoing clinical trials

* COLLABORATION REVENUE - Revenue from collaboration with Chiesi increased to $13.3 mln from $9.5 mln in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.21

Q3 Net -$48.22

Income mln

Q3 Basic -$0.21

EPS

Q3 $62.41

Operatin mln

g

Expenses

Q3 -$49.11

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Gossamer Bio Inc ( GOSS ) is $9.00, about 74.4% above its November 4 closing price of $2.30

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)